NASDAQ:EPZM - Epizyme, Inc.
$13.65
 $-0.07
-0.51%
4:00PM EDT
2019-07-15
Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule inhibitors of other chromatin modifying proteins (CMPs). The Company's lead product candidate, tazemetostat, is a potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2) histone methyltransferases (HMT), an enzyme that plays an important role in various cancers. The Company is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), and one Phase I study in children with molecularly defined solid tumors. The Company owns the global development and commercialization rights to tazemetostat outside of Japan. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  EPZM     avg for
industry  
  avg for
sector  
42 stocks weight:  48. 86   114. 77   204. 78  
42 stocks rank:  2. 31 K 1. 44 K 810. 33  
# analyst opinions:  9. 00   13. 59   13. 86  
mean recommendation:  1. 60   2. 12   2. 04  

quick ratio:  12. 07   5. 48   1. 89  
current ratio:  12. 55   5. 85   2. 40  

target price low:  14. 00   82. 72   115. 11  
target price avg:  19. 00   104. 42   138. 02  
target price high:  25. 00   130. 64   159. 47  
1-yr high:  15. 12   110. 27   142. 72  
last close:  13. 72   85. 12   126. 54  
50-day avg:  12. 97   86. 06   122. 35  
200-day avg:  10. 68   88. 76   121. 75  
1-yr low:  5. 22   69. 26   100. 63  
volume:  447. 49 K 3. 51 M 5. 53 M
50-day avg volume:  949. 37 K 3. 21 M 4. 22 M
200-day avg volume:  837. 63 K 3. 04 M 4. 75 M

1-day return:  1. 33 % -0. 30 % -1. 01 %
this week return:  2. 69 % -2. 16 % -1. 35 %
12-wk return:  8. 20 % 3. 34 % 8. 69 %
52-wk return:  2. 37 % -1. 76 % 12. 22 %

enterprise value (EV):  930. 34 M 46. 50 B 123. 99 B
market cap:  1. 19 B 40. 77 B 109. 11 B
EBITDA:  -123. 22 M 4. 33 B 8. 19 B
enterprise multiple (EV/EBITDA):  -7. 55   5. 45   12. 05  
enterprise/revenue (EV/R):  31. 44   50. 46   9. 50  
total revenue:  29. 59 M 10. 21 B 40. 60 B
total debt:  11. 46 M 11. 27 B 17. 58 B
debt/equity:  3. 11   57. 36   120. 25  
net income (common):  -121. 84 M 2. 13 B 4. 27 B

shares outstanding:  69. 48 M 551. 08 M 1. 24 B
shares:  76. 12 M 559. 41 M 1. 22 B
shares short:  5. 00 M 11. 15 M 11. 94 M
shares short prior month:  4. 28 M 9. 31 M 11. 96 M
short ratio:  5. 52   5. 72   3. 43  
short % of float:  7. 42 % 6. 40 % 2. 65 %
total cash/share:  4. 09   11. 00   9. 23  
total cash:  371. 15 M 6. 03 B 6. 01 B
free cash flow:  -79. 40 M 3. 02 B 4. 96 B
operating cash flow:  -122. 82 M 3. 92 B 5. 99 B

book value:  3. 64   13. 02   27. 49  
price/book:  3. 77   4. 21   8. 80  
gross profits:  -84. 13 M 7. 67 B 36. 29 B
operating margins:  -419. 43 % -380. 20 % -38. 44 %
EBITDA margins:  0. 00 % 13. 59 % 23. 24 %
profit margins:  0. 00 % 10. 94 % 14. 00 %
gross margins:  -261. 96 % 36. 11 % 55. 16 %

1-yr max volatility:  32. 76 % --- ---
1-yr mean volatility:  3. 02 % 1. 50 % 1. 08 %

1-yr EPS:  -1. 62   2. 12   4. 26  
forward EPS:  -1. 79   3. 47   7. 14  
P/E:  -8. 46   2. 15   33. 17  
forward P/E:  -7. 56   -4. 03   17. 60  
PE/G:  0. 90   0. 54   0. 34  
growth:  -9. 43 % 263. 03 % 78. 34 %
earnings high:  -0. 47   0. 91   1. 70  
earnings avg:  -0. 53   0. 71   1. 58  
earnings low:  -0. 61   0. 48   1. 46  
revenue high:  10. 00 M 2. 64 B 11. 26 B
revenue avg:  1. 75 M 2. 58 B 11. 09 B
revenue low:  -0. 00   2. 54 B 10. 90 B
return on assets:  -23. 05 % -2. 31 % 5. 31 %
return on equity:  -39. 67 % -82. 48 % 135. 30 %
revenue/share:  0. 39   12. 77   61. 38  

beta (1yr vs S&P500):  1. 99   1. 26   0. 91  
sharpe (1yr):  0. 40   0. 07   0. 77  

held % insiders:  4. 94 % 6. 08 % 3. 31 %
held % institutions:  93. 24 % 78. 36 % 69. 61 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-07-14 : EPZM
.    118.487 =       118.487 :: --> INITIAL WEIGHT <--
.    - 1.622 =       116.865 :: earnings per-share addition
.                               --> FUNDAMENTALS <--
.    x 2.171 =       253.659 :: P/E factor
.    x 1.028 =       260.654 :: PE/G factor
.    x 1.397 =       364.145 :: beta factor
.    x 0.781 =       284.576 :: sharpe factor
.    x 2.143 =       609.961 :: current ratio factor
.    x 1.044 =       636.918 :: quick ratio factor
.    x 1.087 =        692.21 :: short ratio factor
.    x 1.623 =      1123.501 :: EV/R factor
.    x 1.045 =      1174.126 :: price-to-book factor
.    x 2.581 =      3030.401 :: debt-to-revenue factor
.    x 1.027 =      3111.524 :: debt-to-equity factor
.                               --> PERFORMANCE <--
.    x 2.114 =      6577.714 :: sector+industry 1-year gains factor
.    x 1.033 =      6797.397 :: industry 12-weeks return factor
.    x 1.305 =      8872.463 :: industry 2-weeks return factor
.    x 1.016 =      9017.051 :: company one-year gains+dividend factor
.    x 3.317 =      29908.05 :: company 13 weeks' performance factor
.    x 1.552 =     46424.335 :: 5-day avg > 200-day avg
.    x 1.213 =     56316.369 :: 5-day avg > 50-day avg
.    x 1.215 =     68396.363 :: 50-day avg > 200-day avg
.    / 2.062 =     33165.113 :: overall "drift" factor
.     x 0.76 =     25211.807 :: largest single-day jump factor
.    x 0.289 =      7286.649 :: low price factor
.    x 1.611 =     11741.155 :: notable returns + performance factor
.    x 3.185 =     37393.331 :: inverse volume-to-price factor
.                               --> PROJECTIONS <--
.    x 0.831 =     31067.659 :: forward EPS factor
.    x 0.939 =     29157.884 :: forward P/E factor
.    x 1.182 =     34477.706 :: industry recommendation factor
.    x 2.914 =    100469.937 :: company recommendation factor
.    x 1.008 =    101238.366 :: factor historical industry gain for week 28
.    x 1.177 =    119182.399 :: target low factor
.    x 1.207 =     143827.51 :: target mean factor
.    x 1.038 =    149304.838 :: target high factor
.   x 10.779 =   1609368.151 :: spline projection factor
.                               --> FINAL ADJUSTMENTS <--
.  quad root =        35.618 :: reduced for readability
.   + 12.248 =        47.866 :: add/subtract for investor sentiment
.    + 0.999 =        48.865 :: earnings report in 16 days
.                               --> FINAL WEIGHT <--
.                     48.865 :: FINAL WEIGHT for NASDAQ:EPZM


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org